Skip to main content

JWH-073 Facts

Cannabinoid; Naphthoylindole; Cannabinoid CB1 receptor partial agonist

Description

JWH-073 is a synthetic cannabinoid of the naphthoylindole class. It activates cannabinoid receptors in the brain as a full agonist, with no ceiling on how strong the effect can get.[1]

Subjective effects include euphoria, sedation, appetite enhancement, and pain suppression. The experience resembles cannabis compressed into a shorter window — low doses bring deep relaxation, but a narrow margin separates comfort from adverse territory, with anxiety and disorientation arriving quickly as the dose rises.[2]

JWH-073 produces physical and psychological dependence, and its toxicity profile is steeper than cannabis.[3][4] Full agonism means no ceiling — effects can escalate to seizures, heart emergencies, and multi-organ failure without the natural limit that Δ9-THC provides.[4]

Dose and durationby route · individual sensitivity varies

Smoked(mg)
Threshold< 2 mgLight3 – 5 mgCommon5 – 10 mgStrong10 – 15 mgHeavy15+ mg

Starts in 0 – 5 minLasts 1 – 2 hoursAfter-effects 1 – 2 hours

Body and dependence

Acute toxicity
Moderate
Chronic toxicity
Low
Physical dependence
Moderate
Psychological dependence
Moderate
Withdrawal
Moderate
Compulsive redosing
Moderate

Tolerance

Builds
Rapid
Fully resets after
10.5 days
Carries over to
THC; JWH-018; JWH-250; cannabinoids (all CB1 agonists)

Effectslikely at a common dose

Perception
none likely · 10 possible, including Visual acuity suppression, Vestibular distortion, Spatial disorientation
Body
Body high; Dry mouth; +17 possible, including Vasoconstriction, Motor control impairment, Dehydration sensation
Thinking
none likely · 17 possible, including Cognitive impairment, Memory suppression, Analysis suppression
Feeling
none likely · 5 possible, including Anxiety, Paranoia, Emotional lability
Self
none likely · 3 possible, including Craving
Time
none likely · 3 possible, including Temporal disorientation

Who shouldn't take it

Absolute
History of cardiac arrhythmia or structural heart disease; History of psychosis or schizophrenia; Pregnancy and breastfeeding
Relative
Seizure disorder or history of seizures; Adolescent or young adult use; Concurrent sympathomimetic substance use

Combinations60 recorded

Dangerous (11)
Ketamine, DXM, PCP; Opioids; GHB, Baclofen; GHB, GBL; Ibogaine; Local anesthetics; MAOIs; NDRIs (Wellbutrin); Salvia, Ibogaine; SNRIs; Synthetic cannabinoids
Caution (34)
See full page: psychedex.org/substances/jwh-073
Not graded (15)
Not listed never means safe.

Seek help immediately if

Natural cannabis rarely causes a medical emergency — "greening out" is: pale/sweaty skin, dizziness, nausea or vomiting, anxiety or panic, rapid heartbeat, feeling faint — and usually passes with rest.

Seek emergency help for these — far more likely with synthetic cannabinoids ("spice" / K2):

  • Seizures
  • Severe chest pain; very fast or irregular heartbeat
  • Unresponsiveness or extreme drowsiness
  • Severe agitation, aggression, or psychosis
  • Repeated vomiting; difficulty breathing

What to do

  1. Sit or lie them down somewhere calm, cool, and quiet
  2. Reassure them — cannabis panic and "greening out" pass with time
  3. Offer sips of water; a little sugar can help if they feel faint
  4. Recovery position if nauseated, drowsy, or vomiting
  5. Stay with them and monitor
  6. For seizures, chest pain, unresponsiveness, or severe agitation, call emergency services

Natural cannabis "greening out" resolves with rest, calm, and time, with no lasting harm. Synthetic cannabinoids are unpredictable and can cause seizures, cardiac events, kidney injury, and severe agitation that needs emergency care.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r1 · Not medical advice

References

  1. [1]
    ^Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL (2012) Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity — Biochemical Pharmacology doi:10.1016/j.bcp.2012.01.004
  2. [2]
    ^Simmons J, Cookman L, Kang C, Skinner C (2011) Three cases of spice exposure — Clinical Toxicology doi:10.3109/15563650.2011.584316
  3. [3]
    ^Cooper ZD (2016) Adverse Effects of Synthetic Cannabinoids: Management of Acute Toxicity and Withdrawal — Current Psychiatry Reports doi:10.1007/s11920-016-0694-1
  4. [4]
    ^abTait RJ, Caldicott D, Mountain D, Hill SL, Lenton S (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment — Clinical Toxicology doi:10.3109/15563650.2015.1110590
Print version
Report an issue